Puma Biotechnology: Revenue Projections for 2018
According to Puma Biotechnology’s (PBYI) third-quarter earnings conference call, the company expects NERLYNX’s net product revenues to be $175 million–$200 million for 2018. The company has provided a conservative guidance range—assuming that there might be lower patient starts in November and December due to the holidays.